Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins

Abstract

Current Controlled Trials ISRCTN48110081.

The Role of Aspirin in the Prevention of Cardiovascular Disease

“…10 An additional concern of the CVS is the age of the primary prevention trials, which occurred before the widespread use of other prevention therapies such as statins. 10,17 As such, additional studies are currently ongoing including the Aspirin in Reducing Events in the Elderly (ASPREE) study, 44 Aspirin and Simvastatin Combination for CV Events Prevention Trial in Diabetes (ACCEPT-D), 45 and A Study of Cardiovascular Events in Diabetes (ASCEND). 46 The ASPREE trial is being conducted jointly in the United States and Australia to compare use of low-dose aspirin to a placebo control in patients age 65 and older over a period of 5 years.…”

Diabetes and Aspirin Resistance

“…The ongoing trials that will provide insights into the appropriateness of aspirin usage in diabetic patients include the Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D). (De Berardis, Sacco et al 2007) Results of the Prevention Of Progression of Arterial Disease And Diabetes (POPADAD) trial have been reported, with no benefit with aspirin or antioxidants in primary prevention of cardiovascular events. (Belch, MacCuish et al 2008) ADA recommends enteric-coated aspirin at a dosage of 81-325 mg to be used as a preventive strategy in high-risk diabetic individuals.…”

2016 European Guidelines on cardiovascular disease prevention in clinical practice

“…471 The results of the four major ongoing primary prevention trials-two in DM patients, 472,473 one in individuals of advanced age 474 and one in individuals with moderate CV risk 475 -are expected to become available over the next 5 years.…”